Balyasny Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Balyasny Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.2M	Buy	511,336 +370,758	+264%	+$6.14M	0.01%	1142
2026 Q1	$2.6M	Sell	140,578 -446	-0.3%	-$7.83K	﹤0.01%	1672
2025 Q4	$2.2M	Buy	+141,024	New	+$2.02M	﹤0.01%	1804
2025 Q3	–	Sell	-12,217	Closed	-$189K	–	3456
2025 Q2	$189K	Buy	12,217 +444	+4%	+$6.56K	﹤0.01%	2611
2025 Q1	$175K	Sell	11,773 -181,430	-94%	-$2.54M	﹤0.01%	2612
2024 Q4	$2.56M	Buy	+193,203	New	+$2.65M	﹤0.01%	1582
2024 Q2	–	Sell	-15,354	Closed	-$213K	–	3099
2024 Q1	$213K	Buy	+15,354	New	+$223K	﹤0.01%	2377
2023 Q4	–	Sell	-21,007	Closed	-$325K	–	2892
2023 Q3	$325K	Sell	21,007 -12,338	-37%	-$191K	﹤0.01%	1881
2023 Q2	$524K	Buy	+33,345	New	+$546K	﹤0.01%	1844
2022 Q4	–	Sell	-56,522	Closed	-$733K	–	3224
2022 Q3	$733K	Buy	56,522 +41,686	+281%	+$580K	﹤0.01%	1924
2022 Q2	$208K	Buy	+14,836	New	+$212K	﹤0.01%	2195
2021 Q3	–	Sell	-58,677	Closed	-$988K	–	2409
2021 Q2	$988K	Buy	+58,677	New	+$999K	﹤0.01%	1286
2020 Q2	–	Sell	-15,844	Closed	-$241K	–	1471
2020 Q1	$241K	Buy	+15,844	New	+$287K	﹤0.01%	1029
2019 Q2	–	Sell	-344,714	Closed	-$7.02M	–	1720
2019 Q1	$7.02M	Buy	+344,714	New	+$6.94M	0.05%	481

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Balyasny Asset Management's TAK Position: Q2 2026 in Review

Balyasny Asset Management increased its Takeda Pharmaceutical (TAK) stake by 264% in Q2 2026, buying an estimated $6.14M and bringing the position to 511,336 shares worth $8.2M. The position accounts for 0.01% of the portfolio, ranked #1142.

Balyasny Asset Management first reported a position in TAK in Q1 2019 and has held it in 14 quarters since. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Balyasny Asset Management held 511,336 shares of Takeda Pharmaceutical worth $8.2M as of Q2 2026.
Balyasny Asset Management bought 370,758 Takeda Pharmaceutical shares in Q2 2026, an estimated $6.14M.
Takeda Pharmaceutical made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1142 holding.
Balyasny Asset Management first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 14 quarters since.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.